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SUMMARY
Chronically activated leukocytes recruited to premalignant tissues functionally contribute to
cancer development; however, mechanisms underlying pro- versus anti-tumor programming of
neoplastic tissues by immune cells remain obscure. Using the K14-HPV16 mouse model of
squamous carcinogenesis, we report that B cells and humoral immunity foster cancer development
by activating Fcγ receptors (FcγRs) on resident and recruited myeloid cells. Stromal accumulation
of autoantibodies in premalignant skin, through their interaction with activating FcγRs, regulate
recruitment, composition, and bioeffector functions of leukocytes in neoplastic tissue, which in
turn promote neoplastic progression and subsequent carcinoma development. These findings
support a model in which B cells, humoral immunity, and activating FcγRs are required for
establishing chronic inflammatory programs that promote de novo carcinogenesis.
INTRODUCTION
Clinical, epidemiological, and experimental studies have established that chronic
inflammation contributes to various aspects of solid tumor development (de Visser et al.,
2006; Mantovani et al., 2008). In particular, chronic inflammatory diseases, including
several autoimmune disorders, are associated with increased risk of cancer development
(Brandtzaeg et al., 2006; Dalgleish and O'Byrne, 2002), revealing that B cell hyperactivity
combined with altered cellular immunity cooperate to initiate and/or sustain persistent
inflammation that enhances overall cancer risk in afflicted tissues.
Deposition of B lymphocyte-derived immunoglobulins (Igs) is a common occurrence in
premalignant and malignant stroma of human cancers (de Visser et al., 2006; Tan and
Coussens, 2007). In addition, high levels of circulating immune complexes (CIC) are
associated with increased tumor burden and poor prognosis in patients with breast,
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genitourinary, and head and neck malignancies (Tan and Coussens, 2007). While little is
known about the function of CICs in tumor development, the role of CICs in inflammatory
and autoimmune diseases is undisputed. CIC deposition in stroma has been implicated as an
initiator of inflammatory cascades by mechanisms that include activation of complement
pathways and engagement of the receptors for the crystallizable region (Fc) of IgG (FcγRs)
on the surface of leukocytes (Takai, 2005). As such, FcγRs represent a functional link
between adaptive and innate immunity by coupling interactions between circulating
(auto)antibodies and innate immune cells (Nimmerjahn and Ravetch, 2008).
Four classes of IgG receptor FcγRs have been identified, FcγRI/CD64, FcγRII/CD32,
FcγRIII/CD16, and FcγRIV, differing by their distinct affinity for IgG isotypes, cellular
distributions, and effector functions (Nimmerjahn and Ravetch, 2008). Activating types of
FcγRs form multimeric complexes including the Fc receptor common γ chain (FcRγ) that
contains an intracellular tyrosine-based activating motif (ITAM), whose activation triggers
oxidative bursts, cytokine release, phagocytosis, antibody-dependent cell-mediated
cytotoxicity, and degranulation (Takai, 2005). In contrast, engagement of FcγRIIB (or
FcγRII in mice), which contains an immune tyrosine-based inhibitory motif, abrogates
ITAM-mediated inflammatory responses and instead regulates alternative signaling cascades
(Takai, 2005). FcRγ expression is necessary for assembly and cell-surface localization of
FcγRI, FcγRIII, and FcγRIV; as such, FcRγ−/− mice (Takai et al., 1994) are deficient for all
activating FcγRs, whereas FcγRII expression is unaltered. Given that developing solid
tumors display similar characteristics to tissues damaged by autoimmune dysfunction, e.g.,
chronic immune cell infiltration, tissue remodeling, angiogenesis, and altered cell survival
pathways, we speculated that similar humoral immune-mediated regulatory pathways may
be involved in solid tumor development.
Using a transgenic mouse model of multistage epithelial carcinogenesis, i.e., K14-HPV16
mice (Coussens et al., 1996), we previously revealed that adaptive immunity is an important
regulator of inflammation-associated cancer development (de Visser et al., 2005). Combined
B and T lymphocyte deficiency in HPV16 mice, e.g., HPV16/RAG1−/− mice, resulted in a
failure to initiate and/or sustain leukocyte infiltration during premalignancy (de Visser et al.,
2005). As a consequence, tissue remodeling, angiogenesis, and epithelial hyperproliferation
were significantly reduced, culminating in attenuated premalignant progression and a 43%
reduction in carcinoma incidence (de Visser et al., 2005). Importantly, adoptive transfer of B
lymphocytes or serum from HPV16 mice into HPV16/RAG1−/− mice reinstated chronic
inflammation in premalignant tissues, indicating that B cell-derived soluble mediators were
necessary to potentiate malignant progression. In the present study, we investigated whether
B cell-derived IgGs regulate neoplastic progression and subsequent carcinoma development
by engagement of FcγRs expressed on resident and recruited immune cells.
RESULTS
Humoral Immunity-Mediated Promotion of Squamous Carcinogenesis in HPV16 Mice
HPV16 mice express the early region genes of human papilloma-virus type 16 (HPV16)
under control of the human keratin 14 promotor/enhancer (Arbeit et al., 1994). By 1 month
of age, HPV16 mice develop epidermal hyperplasias with 100% penetrance characterized by
a terminally differentiated hyperproliferative epidermis. Between 3 and 6 months of age,
hyperplastic lesions advance focally into angiogenic dysplasias with prominent
hyperproliferative epidermis that fails to undergo terminal differentiation and a dermis
containing significant CD45+ leukocyte infiltration encompassing CD117+ mast cells and
CD11b+Gr1+ immature myeloid cells (IMCs; Coussens et al., 1999; de Visser et al., 2005;
Junankar et al., 2006) (Figures 1A–1H). By 1 year of age, 60% of HPV16 mice (FVB/n,
N25) develop malignant skin carcinomas, 50% of which are squamous cell carcinomas
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(SCCs) that metastasize to regional lymph nodes with a ~30% frequency (Coussens et al.,
1996). HPV16 mice lacking mast cells (Coussens et al., 1999), leukocyte-derived matrix
metalloproteinase (MMP)-9 (Coussens et al., 2000), or B and T lymphocytes, e.g., HPV16/
RAG1−/− mice (de Visser et al., 2005), exhibit attenuated parameters of premalignant
progression culminating in reduced SCC development.
Given that adoptive transfer of B cells or serum (isolated from HPV16 mice) into HPV16/
RAG1−/− mice restored hallmarks of premalignant progression (de Visser et al., 2005), we
hypothesized that humoral immunity represented the critical feature of premalignant
progression regulating chronic inflammation. To investigate this, we generated HPV16 mice
deficient for B220+CD19+ mature B cells (Chen et al., 1993), e.g., HPV16/JH−/− mice
(Figure S1A, available online). Similar to HPV16/RAG1−/− mice, HPV16/JH−/− mice
exhibited reduced infiltration of premalignant skin by CD45+ leukocytes, including mast
cells and Gr1+ myeloid cells (Figures 1A–1C). Whereas CD11b+Gr1+F4/80−CD11c− IMCs
constitute the most abundant CD45+ leukocyte subtype in premalignant HPV16 skin
(Figures 1D and 1E), immune cell infiltrates in HPV16/JH−/− mice instead revealed an
increased relative proportion of CD11b+Gr1− cells (Figure 1D) that contained F4/80+ and
CD11c+ cells (Figure 1E), as well as expanded populations of CD3+CD4+ and CD3+CD8+ T
cells (Figure 1D). In addition, HPV16/JH−/− mice exhibited reduced presence of CD31+
blood vessels (Figure 1F), vascular endothelial growth factor (VEGF), and MMP-9 protein
levels (Figure 1G and Figure S1B); reduced keratinocyte hyperproliferation (Figure 1H);
and diminished presence of focal dysplastic lesions (Figure 1I). Together, these data indicate
that B cells are critical components of adaptive immunity regulating premalignant
progression and characteristics of early squamous carcinogenesis in HPV16 mice.
HPV16-Induced Autoantibody Complexes Induce Acute Inflammation
Because parameters of premalignant progression were reinstated in HPV16/RAG1−/− mice
by adoptive transfer of serum from HPV16 animals, and because dysplastic skin of HPV16
mice is characterized by stromal depositions of IgG and IgM (de Visser et al., 2005), we
hypothesized that Igs were the mediators by which B cells promote premalignant
progression. To assess this, we first evaluated CIC presence in serum of HPV16 mice and
found increased concentrations paralleling premalignant progression (Figure 2A). Using
direct immunofluorescence with biotinylated IgGs isolated from HPV16 serum (IgGHPV16)
as detector antibodies, we revealed that IgGHPV16 cognate antigens were localized to both
epithelial and dermal compartments of neoplastic skin (Figure 2B, inset). In addition to
HPV16 E7 oncoprotein-specific autoantibodies (Figure S2) (Daniel et al., 2005), we
identified high titer IgGs specific for type I, II, and IV collagens, but not laminins 111 and
332 (Figure 2B).
To determine whether stromal deposition of autoantibodies was sufficient to induce an acute
inflammatory response in vivo, we injected IgGHPV16 versus IgG isolated from negative
littermate mice (IgGwt) intradermally into syngeneic FVB/n mice. While IgGHPV16 and
IgGwt antibodies were similarly detected in dermis (Figure 2C), only mice injected with
IgGHPV16 exhibited an acute inflammatory response characterized by a significant increase
in CD45+ and Gr1+ cell recruitment (Figure 2D). Since similar concentrations of IgGHPV16
versus IgGwt differentially induced leukocyte recruitment in vivo, we hypothesized that
higher proportions of IgGHPV16 as opposed to IgGwt were present in their active form, e.g.,
in immune complexes (ICs), and indeed, we found that IgGHPV16 contains significantly
higher levels of both IgG/C3 and IgG/C1q ICs as compared to IgGwt (Figure 2E).
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Differential Expression of FcγR Ig Receptors on Leukocytes in HPV16 Neoplastic Skin
Premalignant progression in HPV16 mice is independent of complement cascade activation
via complement factor C3 (de Visser et al., 2004); thus, we hypothesized that CICs
accumulating in young HPV16 mice promoted neoplastic progression through activation of
FcRγ signaling. FcγRs are broadly expressed on immune cells and encompass both
activating, e.g., FcγRI, III, and IV (including the FcRγ subunit), and inhibitory, e.g., FcγRII,
subtype complexes (Nimmerjahn and Ravetch, 2008). Immunodetection of FcRγ, FcγRI,
and FcγRII/III revealed increased presence of CD45+FcγR+ cells in dermal regions of
premalignant HPV16 skin (Figure 3A). Using flow cytometry, we revealed that while
CD11b+Gr1+ IMCs and CD45+CD117+ mast cells expressed FcγRIII, CD11b+Gr1− cells,
including F4/80+ macrophages and CD11c+ dendritic cells (DCs), expressed FcγRI and
FcγRIII, and no expression of any FcγR was detected on CD3+ T cells or CD45−
nonimmune cells in neoplastic skin (Figure 3B). B cells were not evaluated given their
undetectable levels in HPV16 skin (Figure 1D) (de Visser et al., 2005).
Leukocyte FcRγ Is Necessary for Tumor Development and Squamous Carcinogenesis
Because IgGHPV16 induced acute inflammatory responses in syngeneic nontransgenic mice,
and proinflammatory-type FcγRs were expressed on infiltrating leukocytes in premalignant
HPV16 skin, we evaluated whether carcinoma growth or de novo squamous carcinogenesis
were FcγR dependent. First we assessed transplantable tumor growth with syngeneic
FcRγ−/− (Takai et al., 1994) versus FcRγ+/− mice injected subcutaneously with PDSC5
cells, a carcinoma cell line derived from a poorly differentiated SCC (Arbeit et al., 1996).
Mice lacking FcRγ failed to mount a robust angiogenic response (Figure 3C) as well as to
support transplantable tumor growth (Figure 3D), which was independent of humoral
immune responsiveness as serum Ig titers increased in PDSC5-injected mice irrespective of
FcRγ expression (Figure 3D).
To evaluate whether de novo tumorigenesis was similarly FcRγ dependent, we generated a
cohort of HPV16/FcRγ−/− mice that retained expression of inhibitory FcγRII (Figure S3A).
Quantitative evaluation of CD45+ immune cell infiltrates in neoplastic skin by flow
cytometry revealed reduced leukocyte infiltration in HPV16/FcRγ−/− mice as compared to
age-matched HPV16/FcRγ+/− tissue (Figure 4A). Similar to HPV16/JH−/− mice, mast cells
and IMCs were significantly reduced in HPV16/FcRγ−/− mice, concomitant with an
increased relative influx of CD11b+Gr1− macrophages and DCs, as well as CD3+CD4+ and
CD3+CD8+ lymphocytes (Figures 4B–4D). F4/80 and CD11c lineage marker expression on
both CD11b+Gr1+ and CD11b+Gr1− cells were unperturbed by absence of FcRγ (Figure 4E
and Figure S3D). FcγRIII-expressing CD45+CD49b+CD3− NK cells represented a minor
population in control HPV16 skin, recruitment of which was not modified by FcRγ
deficiency (Figures S3B and S3C).
To determine whether the activating types of FcγRs also mediated other parameters of de
novo squamous carcinogenesis, we analyzed age-matched HPV16/FcRγ−/− mice at
canonical time points (1, 4, and 6 months of age) and found reduced development of
angiogenic vasculature (Figure 4F), VEGF, and MMP-9 protein levels (Figure 4G and
Figure S3E); reduced keratinocyte hyperproliferation and appearance of focal dysplastic
regions (Figures 4H and 4I); and significantly reduced incidence of SCC development
(Figure 4I). Diminished de novo carcinogenesis in HPV16/FcRγ−/− mice was independent
of B cell responses and humoral immunity as shown by Ig isotype switching and
accumulation of IgG1 and IgG2a in HPV16/FcRγ−/− mice (Figure S3F). Our interpretation of
these findings was that peripheral activation of humoral immunity in young HPV16 mice
promoted squamous carcinogenesis by locally activating FcRγ-mediated signaling on
resident and recruited immune cells in neoplastic skin. These in turn activate angiogenic
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programs in vascular cells, thus enabling tissue expansion via keratinocyte
hyperproliferation, culminating in increased SCC development.
Mast Cell FcRγ Activation Regulates Parameters of Premalignant Progression and
Enhances Tumor Development
Given that we found that combinations of activating FcγRs were expressed on infiltrating
leukocytes in HPV16 skin, and given that absence of either humoral immunity or FcRγ
altered leukocyte composition during premalignant composition, we sought to delineate
which distinct FcRγ+ leukocyte population exhibited protumorigenic properties.
FcγRIII+ mast cells regulate tissue remodeling, angiogenesis, and keratinocyte
hyperproliferation in HPV16 mice (Coussens et al., 1999; Coussens et al., 2000), thus we
evaluated whether FcRγ-dependent activation of mast cells was in part necessary for
neoplastic progression. Using conditioned medium generated from FcRγ-deficient versus
FcRγ-proficient bone marrow-derived mast cells (BMMCs) previously stimulated with
either rat IgG, IgGHPV16, or IgGwt, we found that Ig-activated mast cells induced human
umbilical vein endothelial cell (HUVEC) migration (Figure 5A), VEGF expression (Figure
5B), and CD45+ peripheral blood leukocyte (PBL) recruitment (Figure 5C), which were
dependent on FcRγ expression. The diminished capabilities of FcRγ-deficient mast cells
were conserved in vivo as PDSC5 tumor growth was significantly diminished in mast cell-
deficient (kitsh/sh) mice, whereas presence of FcRγ-proficient BMMCs significantly
enhanced tumor growth, development of angiogenic vasculature, and infiltration by Gr1+
leukocytes (Figures 5D and 5E). These features were not significantly altered in PDSC5
tumors grown in the presence of FcRγ−/− BMMCs as compared to PDSC5 cells alone
(Figure 5E). Thus, these findings support a model in which mast cells respond to CIC
deposition in early neoplastic stroma by activating FcγR-mediated pathways, leading to PBL
recruitment and angiogenesis, which together establish a microenvironment permissive for
tumor development.
FcRγ-Independent and -Dependent Properties of CD11b+ Myeloid Cells in HPV16 Mice
As described both in cancer patients and mice harboring some transplantable tumors
(Ostrand-Rosenberg, 2008), CD11b+Gr1+ cells accumulate in spleen and peripheral blood of
HPV16 mice (Figure S4A). Morphological analysis of CD11b+Gr1+ cells isolated from
neoplastic skin and spleen of HPV16 mice revealed characteristics of immature
granulocytes, including presence of elongated band-shaped, nonfragmented nuclei (Figure
6A) in cells encompassing a mixed population expressing CD45, 7/4, CD14, CD44, IL4Rα,
CD80, and CD86, but not CD34 (Figure S4B). In contrast, CD11b+Gr1− cells (from skin)
accumulate only in draining lymph nodes of HPV16 mice (Figure S4A), exhibited a more
mature phenotype with larger cellular diameters, dense granules, vacuole-rich cytoplasm,
and round nuclei (Figure 6A), and reflected subpopulations orientated toward dendritic
(CD11c+) and macrophage lineages (F4/80+) (Figure S4B).
To delineate which distinct FcRγ+ myeloid population present in HPV16 neoplastic skin
exerted FcRγ-dependent protumor properties, and considering the fact that differential
activation of FcγRs regulates DC maturation (Takai, 2005), we evaluated expression of
CD86, CD80, and MHC-II by flow cytometry in CD11b+Gr1−CD11c+F4/80− DCs from
cervical lymph nodes and premalignant skin of HPV16/FcRγ+/− and HPV16/FcRγ−/− mice
and found no significant differences (Figure S5A). Similarly, when we audited gene
expression of CD11b+Gr1−CD11c+F4/80− skin DCs isolated from age-matched HPV16/
FcRγ+/− and HPV16/FcRγ−/− mice by low-density qPCR arrays, we found no change in
expression of genes reflecting DC maturation. However, HPV16/FcRγ−/− DCs reflected
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myeloid population polarized toward a TH1 state as shown by enhanced expression of Nos2,
IL1a, IFNg, IL12a, Ptgs2, and IL6 (Figure S5B and Table S1).
CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) have been reported to promote
tumor development by enhancing angiogenesis and by inhibiting T lymphocyte-mediated
anti-tumor immunity (Ostrand-Rosenberg, 2008). Since CD11b+Gr1+ accumulate in HPV16
neoplastic tissue and peripheral sites and exhibit an immature morphology (Figure 6A and
Figure S4B), we assessed their immune-suppressive capabilities as compared to
CD11b+Gr1+ cells isolated from tumors and spleens of 4T1 mammary tumor-bearing mice,
a model where immune-suppressive properties of MDSCs have been previously described
(Figure S5C) (Ostrand-Rosenberg, 2008). Neither CD11b+Gr1+ cells isolated from
premalignant skin nor from spleen of HPV16 mice demonstrated in vitro inhibition of
polyclonal activation of either CD4+ or CD8+ T cells (Figure S5C). In addition,
CD11b+Gr1+ cells failed to produce reactive oxygen species, major mediators implicated in
myeloid-mediated immune suppression (Figure S5D) (Ostrand-Rosenberg, 2008).
Moreover, using low-density qPCR arrays, gene expression analysis of HPV16/FcRγ−/−
versus HPV16/FcRγ+/− skin CD11b+Gr1+ cells revealed downregulation of IL1a, Ptgs2, and
TNFα, indicative of a diminished proinflammatory state (Figure S5E and Table S1).
Moreover, when co-injected with PDSC5, CD11b+Gr1+ cells isolated from skin of HPV16
mice failed to alter either tumor growth or development of angiogenic vessels (Figures 6B
and 6C) and did not exhibit proangiogenic activity in vitro (Figure 6D). Thus, although
present in significant numbers, CD11b+Gr1+ cells infiltrating neoplastic skin are likely to
represent a population of bona fide immature cells.
FcRγ Activation Mediates the Protumor and Angiogenic Bioactivities of CD11b+Gr1−F4/80+
Macrophages
In contrast to IMCs, both spleenic and skin CD11b+Gr1−CD11c−F4/80+ macrophages
induced HUVEC migration in vitro by a FcRγ-dependent mechanism (Figure 6D) and
significantly enhanced PDSC5 tumor growth in vivo (Figures 6B and 6C). Moreover,
macrophage-enhanced tumorgenicity of PDSC5 cells was also FcRγ dependent (Figures 7A
and 7B). Interestingly, bone marrow-derived FcRγ−/− macrophages, when admixed with
PDSC5 cells, not only failed to promote transplantable tumor development but also impeded
tumor growth (Figure 7B).
Given that DC gene expression analyses revealed altered programming toward a TH1-type
state, we reasoned that perhaps, similarly, in the absence of FcRγ signaling, macrophages
were also reprogrammed. Indeed, using low-density qPCR arrays and RT-PCR, gene
expression analyses of macrophages isolated from HPV16/FcRγ+/− versus HPV16/FcRγ−/−
skin revealed significant upregulation of genes reflecting classical “M1” activation,
including Il1b, Il12a, Cxcl10, Nos2, Cxcl11, and IL1a, whereas genes reflecting alternative
“M2” (Il13, Cd163, Ccl17, Il4, and Ym1) or “M2-like” (Ccl1) activation were significantly
downregulated in HPV16/FcRγ−/− as compared to HPV16/FcRγ+/− macrophages (Figure
7C).
Among the differentially expressed genes, the angiostatic chemokines Cxcl10 and Cxcl11
were significantly elevated in HPV16/FcRγ−/− macrophages (Figure 7C). We confirmed that
mRNA expression of Cxcl10, as well as its receptor Cxcr3, were significantly upregulated in
whole neoplastic skin of 4-month-old HPV16/FcRγ−/− and HPV16/JH−/−, as compared to
age-matched HPV16/FcRγ+/− skin by qRT-PCR (Figure 7D). Given that VEGF-induced
HUVEC migration was significantly inhibited by CXCL10 in a CXCR3-dependent manner
(Figure 7E), we evaluated FcRγ-deficient versus FcRγ-proficient macrophages isolated from
the respective HPV16 cohorts and revealed CXCR3-dependent angiostatic activity of
FcRγ−/− macrophages (Figure 7F).
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DISCUSSION
We revealed a provocative and functional role for B cells and activating type FcγRs as
potentiators of squamous carcinogenesis. Using a transgenic mouse model of epithelial
carcinogenesis and mice lacking either B cells or activating FcγRs, we found that IC
stimulation of leukocyte FcRγ is critical for establishing a protumor microenvironment in
premalignant tissue that directs not only recruitment of leukocytes from peripheral blood but
also leukocyte composition, phenotype, and bioeffector functions once within neoplastic
tissue (Figure 8). As such, proangiogenic and protumorigenic functions of mast cells and
macrophages are differentially regulated by humoral immunity and functionally contribute
to squamous carcinogenesis (Figure 8). These findings have broad clinical implications as
they reveal critical signaling pathways regulated by humoral immunity and FcRγ to target
therapeutically in patients at risk for cancer development, e.g., patients suffering from
chronic inflammatory diseases, as well as individuals harboring premalignant lesions where
chronic inflammation compromises tissue integrity and enhances risk of malignancy.
Regulation of Protumor Immunity by B Cells, Humoral Immunity, and Activating FcγRs
While early and persistent inflammatory-type reactions in or around developing neoplasms
are thought to regulate tumor development (de Visser et al., 2005; Mantovani et al., 2008),
tumor-promoting properties of adaptive leukocytes have not been fully elucidated. As the
central component of humoral immunity, B lymphocytes function in antibody production,
antigen presentation, and secretion of proinflammatory cytokines. In the context of cancer,
in addition to altering local and circulating levels of cytokines, B cells also inhibit TH1-
mediated anti-tumor immunity. In a transplantable model of colorectal cancer, partial B cell
depletion resulted in significantly reduced tumor burden (Barbera-Guillem et al., 2000),
while B cell-deficient mice showed resistance to syngeneic tumors (Shah et al., 2005). In
addition, overexpression of tumor necrosis factor receptor-associated factor 3 in
lymphocytes activates humoral immune responses that result in chronic inflammation and
enhanced incidence of cancer, particularly SCCs (Zapata et al., 2009).
Using HPV16/B cell-deficient mice, we found that pre-malignant progression was
significantly attenuated and essentially stalled at an early hyperplastic stage. In the absence
of B cells, leukocyte recruitment from peripheral blood was reduced, vasculature failed to
mount an angiogenic response, and hyperproliferation of keratinocytes failed to support
tissue expansion to a carcinoma in situ state. Thus, peripheral activation of B cells represents
an early event in premalignant progression that promotes subsequent neoplastic
programming of tissue.
How do B cells “promote” solid tumor formation? It is well known that cancer patients
develop antibodies to tumor-associated antigens—evidence exist for c-myc, HER-2/neu, and
p53 (Lu et al., 2008). In addition, high circulating levels of ICs are associated with increased
tumor burden and poor prognosis in patients with breast, genitourinary, and head and neck
malignancies (Tan and Coussens, 2007). In a chemical carcinogenesis mouse model of
papilloma growth, immunization against an inherited oncoprotein failed to eradicate tumor
cells but rather induced tumor growth (Siegel et al., 2000). Increased levels of Ig in
neoplastic microenvironments result in accumulation of ICs that favor tumor-promoting
inflammatory responses including recruitment and activation of several myeloid cell types
(Barbera-Guillem et al., 1999). When injected into syngeneic nontransgenic mice, CICs
(from HPV16 mice) alone were sufficient to trigger an acute inflammatory response. While
largely not described in the context of cancer, the significance of inflammatory responses to
autoantibodies has been studied in mouse models of autoimmune disease (Nimmerjahn and
Ravetch, 2008) where FcγRs have been recognized as effectors that induce recruitment of
CD11b-expressing myeloid cells into tissue (Bergtold et al., 2006). Thus, mice deficient in
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activating-type FcγRs are resistant to IC-mediated hypersensitive reactions, such as
alveolitis, glomerulonephritis, and skin Arthus reaction, while mice deficient in FcγRII
exhibit enhanced IC-mediated inflammatory responses (Takai, 2005). Herein, we found
differential presence of both activating and inhibitory types of FcγRs on infiltrating myeloid
cells, and using FcRγ-deficient mice, we demonstrated a functional role for the Fc activating
receptors in cancer promotion. Therefore IgG-mediated activation of FcRγ on resident and
recruited leukocytes, including mast cells and macrophages, regulated not only PBL
recruitment but also leukocyte activation and bioeffector function within the neoplastic
microenvironment.
Activation of complement pathways is an alternative mechanism by which IgG could induce
leukocyte activation and recruitment, further leading to chronic inflammation. Markiewski
et al. (2008) reported that transplanted renal tumor growth was regulated by complement
activation and that C5a deposition was associated with MDSC recruitment and subsequent
CTL suppression. Complement factor C3 does not alter parameters of neoplastic progression
in HPV16 mice (de Visser et al., 2005); however, C3-independent mechanisms do exist
(Baumann et al., 2001). As such, we cannot exclude a role for complement factors as sensors
of IC deposition in HPV16 mice, potentially regulating C3-independent FcγR activation.
It is intriguing to speculate that targeting B lymphocyte/Ig/FcγR pathway by inactivating
either B lymphocytes or FcRγ signaling may be tractable for anti-cancer therapy. In support
of this approach, patients with rheumatoid arthritis, systemic lupus erythematosus, and
others, have benefited following B cell-depletion therapy using a chimeric monoclonal
antibody specific to human CD20, e.g., Rituximab (Gurcan et al., 2009). Rituximab has also
shown clinical efficacy in adult acute lymphoblastic leukemia (Gokbuget and Hoelzer,
2006). Support for extending Rituximab into solid tumor therapy comes from a clinical
study with colon cancer patients in which numbers of CD21-hyperpositive lymphocytes
were reduced in parallel with reduction in tumor burden (Barbera-Guillem et al., 2000).
Although Rituximab effectively deletes circulating B cells, no increased susceptibility to
infection has been observed in patients with rheumatoid arthritis or non-Hodgkin's
lymphoma (Gokbuget and Hoelzer, 2006), thus supporting the approach and manipulation of
humoral immunity and/or its downstream effector pathways as a therapeutic possibility.
Programming Recruited Leukocytes and Inhibiting Protumor Immunity
Clinical and experimental data indicate that chronic presence and activation of immune
cells, e.g., mast cells, macrophages, Tie2-expressing monocytes, neutrophils, DCs, IMCs,
and CD4+ T cells, promote tumor development by activating angiogenic programs,
suppressing antitumor immunity (Mantovani et al., 2008), and enhancing tumor cell
migration and metastasis (DeNardo et al., 2009; Pollard, 2008). When chronically activated
in tumor microenvironments, some myeloid cells are programmed such that they deliver a
diversity of bioactive mediators to neoplastic tissues, including chemokines, cytokines,
matrix remodeling enzymes, and cytotoxic proteins (Mantovani et al., 2008). Identification
of the critical programs that induce these protumor pathways would reveal important
mediators to potentially target with anticancer therapeutics.
Mast cells exert duality as cancer mediators with some clinical studies indicating their
presence in human cancers correlates with a favorable clinical outcome, whereas others
clearly implicate them as protumor mediators (Theoharides and Conti, 2004). In HPV16
mice (Coussens et al., 1999), and in other models of cancer development (Nakayama et al.,
2004; Soucek et al., 2007), mast cell-derived factors foster tumor cell survival and
angiogenesis. With IgG-mediated stimulation of mast cells enhancing tumor development
and angiogenesis in HPV16 mice, these data indicate a functional requirement for FcRγ
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engagement for activating protumor cascades, leading to PBL recruitment into neoplastic
skin, angiogenesis, and tumor development.
Pharmacologic inhibition of macrophages minimizes cervical carcinogenesis in HPV16 mice
(Giraudo et al., 2004), whereas elimination of macrophages during mammary carcinogenesis
limits cancer progression and metastasis (Pollard, 2008) by reducing angiogenesis in
premalignant tissues. Interestingly, pro- versus anti-metastatic properties of infiltrating
macrophages in MMTV-PyMT mice are programmed by CD4+ T lymphocytes via an IL-4-
dependent mechanism (DeNardo et al., 2009). In contrast, in ovarian cancer, macrophage
pheno-type is regulated by IL-1R and MyD88, which together maintain a macrophage
immunosuppressive M2 phenotype (Hagemann et al., 2008). In the present study, we report
that B cells and FcRg are key parameters regulating pro- versus antitumor programming of
macrophages during squamous carcinogenesis through a mechanism that not only involves
modified M1 versus M2 or M2-like polarization but also the differential expression of an
angiostatic chemokine Cxcl10 and its receptor Cxcr3. As such, activation of angiogenic
vasculature in developing tumors is regulated by multiple subsets of myeloid cells, each
exhibiting a distinct signature of pro- versus antiangiogenic molecules, as well as likely
being programmed by distinct effector pathways dependent on the tissue microenvironment.
These experimental findings imply that reprogramming myeloid cell phenotypes and/or
altering the immune microenvironment to foster antitumor versus protumor activity could
improve survival of patients with cancer by limiting cancer development and perhaps
stabilizing premalignant or premetastatic disease. Proof-of-concept studies supporting this
notion were recently reported by De Palma et al. (2008) demonstrating that myeloid cells
could be used as vehicles to deliver immune mediators to tumor microenvironments and
essentially reprogram them.
Conclusions
Results from this study demonstrate a key role for B lymphocytes, humoral immunity, and
activation of FcRg signaling pathways in myeloid cells as promoting forces for squamous
carcinogen-esis. With regards to therapy, our data indicate that anti-cancer strategies
targeting B cells, Ig, or FcRγ may harbor therapeutic efficacy in limiting risk of malignant
conversion in patients suffering from chronic inflammatory diseases or in patients harboring
premalignant lesions whose molecular and/or immunologic characteristics favor tumor
development. The efficacy and safety of Rituximab for various autoimmune disorders and
some hematological cancers could be extended to potentially combat squamous neoplasms
in which IC deposition is prominent and/or activation of FcRγ-mediated signaling is evident.
EXPERIMENTAL PROCEDURES
Animal Husbandry
Generation and characterization of HPV16, JH−/−, FcRγ−/−, and c-kitsh/sh mice have
previously been described (Arbeit et al., 1994; Coussens et al., 1996; Lyon and Glenister,
1982; Takai et al., 1994). To generate HPV16 mice in the JH−/− and FcRγ−/− backgrounds,
JH+/− and FcRγ+/− mice were backcrossed into the FVB/n strain to N5 and intercrossed with
HPV16 mice. c-kitsh/+ mice were backcrossed five generations into FVB/n. All mouse
experiments complied with National Institutes of Health guidelines and were approved by
the University of California San Francisco Institutional Animal Care and Use Committee.
Characterization of neoplastic stages has been reported previously (Coussens et al., 1996).
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In Vivo Assays
For evaluation of proinflammatory properties of IgGs, serum-purified IgGs (20 μl; 12 μg/μl)
were injected intradermally into ears of (−)littermates. For performing matrigel plug assays,
PDSC5 cells (Arbeit et al., 1996) (1.5 × 3 106/100 μl) were suspended in 300 ml of Matrigel
and injected s.c. in the groin area of 7-week-old mice. For tumorgenicity assays, PDSC5
cells (0.5 × 3 106 cells) were suspended in 100 ml of Matrigel in PBS (1:1) and inoculated
s.c. into flanks of 7-week-old mice. Tumors were measured at 2 day intervals with a digital
caliper, and tumor volume was calculated with the equation V (mm3)=a × 3 b2/2 (a is the
largest diameter and b the smallest diameter).
Low-Density qPCR Arrays
Immune Panel TaqMan arrays (Applied Biosystems) were used to measure the expression of
96 genes in three biological replicates. Analysis of raw data obtained with Immune Panel
TaqMan arrays have been performed using an implemented covariance model, as previously
described (Pucci et al., 2009).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism version 4 and/or InStat version
3.0a for Macintosh (GraphPad Software). Specific tests included Mann-Whitney (unpaired,
nonparametric, two-tailed), unpaired t test, Fisher's exact test, chi-square test, and log rank
analysis. p values < 0.05 were considered statistically significant.
Significance
Andreu and colleagues demonstrate that peripheral activation of humoral immunity and
subsequent activation of FcγRs on myeloid cells regulate critical features of
carcinogenesis that foster solid tumor development. This work reveals previously
unrecognized targets for therapeutic intervention in solid tumors, namely, B cells and
FcRγ-signaling pathways that work in concert to differentially regulate not only the
composition of leukocytes recruited to premalignant tissues but also their bioeffector
functions once present.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. B Cells Are Critical Regulators of Premalignant Progression in HPV16 Mice
(A) Percentage of CD45+ cells in skin single cell suspensions isolated from negative
littermates (−LM), HPV16/JH+/−, and HPV16/JH−/− mice at 1, 4, and 6 months of age
assessed by flow cytometry.
(B and C) Mast cells (B, blue staining) and Gr1+ myeloid cells (C, brown staining) in skin of
HPV16/JH+/− and HPV16/JH−/− mice at 1, 4, and 6 months of age assessed quantitatively
after chloroacetate esterase histochemistry or Gr1 immunohistochemistry (IHC),
respectively.
(D) Flow cytometric analysis of immune cell lineages expressed as percentages of total
CD45+ leukocyte infiltrates in ear tissue of negative littermates (−LM), HPV16, HPV16/
JH+/−, HPV16/JH−/−, and HPV16/RAG1−/− mice at 1, 4, and 6 months of age.
(E) Dendritic (CD11c+) and macrophage (F4/80+) lineage cell composition of CD11b+Gr1+
(left) and CD11b+Gr1− (right) myeloid populations evaluated by flow cytometry in skin of
negative littermates (−LM), HPV16, and HPV16/JH−/− mice at 4 months of age.
(F) Angiogenic vasculature in skin tissue sections from negative littermates (−LM), HPV16/
JH+/−, and HPV16/JH−/− mice at 1, 4, and 6 months of evaluation by CD31/PECAM-1 IHC
revealing endothelial cells (brown staining).
(G) Reduced VEGF-A and active MMP-9 protein levels in skin extracts from HPV16/JH−/−
versus HPV16/JH+/− mice (4 and 6 months) as assessed by ELISA.
(H) Keratinocyte proliferation in skin of negative littermates (−LM), HPV16/JH+/−, and
HPV16/JH−/− mice at 1, 4, and 6 months of age, as evaluated by quantitation of
bromodeoxyuridine (BrdU)-positive keratinocytes (red staining).
(I) Percentage of ear skin in HPV16/JH−/− and HPV16/JH+/− mice developing hyperplastic
lesions by 1 month of age (Hyp) or dysplasia by 4 and 6 months of age (Dys).
(A–I) Results shown represent mean ± SEM (n = 5–8 mice) and asterisks (*) indicate
statistically significant differences (p < 0.05, Mann-Whitney). Representative images of
HPV16/JH+/− and HPV16/JH−/− mouse skin at 4 months of age are shown. Values represent
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average of five high-power fields of view per mouse and five mice per category. FOV, field
of view; solid red line, epidermal-dermal interface; e, epidermis; d, dermis. Scale bars
represent 50 μm. See also Figure S1.
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Figure 2. CICs from HPV16 Mice Induce Acute Inflammation
(A) CICs titers in serum collected from negative littermate (−LM), HPV16/JH+/+, and
HPV16/JH−/− mice assessed by ELISA with anti-mouse C3 Ig (left) and C1q (right). The
specificity of C1q/IgG binding to ICs was assessed by disrupting C1q-CIC binding using a
high-salt solution (C1q/IC/d; gray bars).
(B) Antibody titers for laminin (Lm)-111, Lm-332, collagen (Col)-I, Col-II, and Col-IV in
serum from littermate (−LM), HPV16, and HPV16/JH−/− (4 months) were evaluated by
indirect ELISA. Antigens recognized by biotinylated IgGHPV16 were localized by
immunofluorescence on skin sections from 4-month-old HPV16 mice (inset; IgGs: red
staining).
(C) Immunofluorescence (green staining) staining on syngeneic skin tissue sections reveals
presence of intradermally injected purified IgGs isolated from negative littermate (IgGwt) or
HPV16 (IgGHPV16) 24 hr after intradermal injections.
(D) Number of infiltrating CD45+ leukocytes and Gr1+ cells in skin tissue sections 24 hr
after intradermal injections of PBS, IgGwt, or IgGHPV16 into ears of syngeneic wild-type
FVB/n mice. Values reflect averages from five high-power fields per mouse.
(E) Normalized CIC titers of IgG purified from negative littermates (IgGwt) or HPV16
(IgGHPV16) serum assessed by ELISA with anti-mouse C3 Ig (left) and C1q (right).
(B and C) Blue staining, DAPI; white line, epidermal-dermal interface; e, epidermis; d,
dermis. Scale bars represent 50 μm.
(B–D) Results shown are mean percentages ± SEM (n = 5–8 mice) and asterisks (*) indicate
statistically significant differences (p < 0.05, Mann-Whitney). See also Figure S2.
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Figure 3. Infiltration of FcγR+ Leukocytes during Neoplastic Progression in HPV16 Mice
(A) Infiltration of leukocytes expressing FcRγ (red staining, top), FcγRI (red staining,
middle), and FcγRII/III (brown staining, bottom) in premalignant skin of HPV16 mice
evaluated in tissue sections by immunofluorescence. Shown in the right panels is double
immunofluorescence staining revealing expression of FcRγ and FcγRII/III on CD45+
leukocytes. Solid line, epidermal-dermal interface; e, epidermis; d, dermis; blue staining,
DAPI. Scale bars represent 50 μm.
(B) Differential expression of FcγRI and FcγRIII by individual leukocyte populations in
premalignant skin of HPV16 (red) and HPV16/JH−/− (blue) mice at 4 months of age. Live
cells were gated as CD45+ leukocytes, CD45+CD3+ T lymphocytes, CD11b+Gr1+ IMCs,
CD11b+Gr1− mixed macrophages/DCs, and CD45+CD117+ mast cells. Grey line, Ig
control.
(C) PDSC5 tumor cells were injected as matrigel plugs into FcRγ+/− and FcRγ−/− mice
(FVB/n). Neovascularization was evaluated by CD31 IHC (brown staining). Values reflect
number of CD31+ vessels averaged from five high-power fields per mouse (n = 5–8 mice).
Scale bars represent 25 μm.
(D) Deficient tumor growth in mice lacking FcRγ. PDSC5 tumor cells were injected s.c. into
FcRγ+/− and FcRγ−/− syngeneic FVB/n mice. Titers of IgG in serum of wild-type (WT)
FVB/n versus transplanted FVB/n mice evaluated by ELISA.
(C and D) Results shown are mean percentages ± SEM. Asterisks (*) indicate statistically
significant differences (p < 0.05, unpaired t test).
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Figure 4. FcRγ Expression Is a Critical Determinant of Squamous Carcinogenesis in HPV16
Mice
(A) Percentage of CD45+ cells in skin of HPV16/FcRγ+/− and HPV16/FcRγ−/− mice at 1, 4,
and 6 months assessed by flow cytometry.
(B and C) Mast cells (B, blue staining) and Gr1+ myeloid cells (C, brown staining) in skin of
HPV16/FcRγ+/− and HPV16/FcRγ−/− mice at 1, 4, and 6 months of age assessed
quantitatively after chloroacetate esterase histochemistry or Gr1 IHC, respectively.
(D) Flow cytometric analysis of immune cell lineages as percentages of total CD45+
leukocytes in single-cell suspensions from nontransgenic, HPV16/FcRγ+/−, and HPV16/
FcRγ−/− transgenic skin at 1, 4, and 6 months of age.
(E) Dendritic (CD11c+) and macrophage (F4/80+) cell composition in CD11b+Gr1+ and
CD11b+Gr1− myeloid populations evaluated by flow cytometry of single cell suspensions
derived from skin of negative littermate (−LM), HPV16, and HPV16/FcRγ−/− mice at 4
months of age.
(F) Attenuated angiogenesis in premalignant skin of HPV16/FcRγ−/− mice. Density of
angiogenic vasculature evaluated quantitatively by CD31 IHC (brown staining) on age-
matched tissue sections.
(G) Reduction in total VEGF-A and active MMP-9 protein levels in skin tissue extracts from
age-matched HPV16/FcRγ−/− and HPV16/FcRγ+/− mice as determined by ELISA.
(H) Keratinocyte proliferation evaluated as percentage of bromodeoxyuridine (BrdU)-
positive keratinocytes (red staining) in ear skin tissue sections representing age-matched
negative littermate (−LM), HPV16/FcRγ+/−, and HPV16/FcRγ−/− premalignant skin.
(I) Percentages of ear skin (area) exhibiting hyperplasia by 1 month of age (Hyp) or
dysplasia by 4 or 6 months of age (Dys). Values represent percentages of mice with specific
neoplastic phenotypes. Statistical significance was determined using the Mann-Whitney test.
Lifetime incidence of SCC was determined in HPV16/FcRγ+/− and HPV16/FcRγ−/− mice
(97 and 132 mice/group, respectively). Tumor incidence was analyzed with the generalized
Wilcoxon test. Hazard ratio was determined by Kaplan Meyer analysis of tumor incidence.
All mice reflect similarly backcrossed groups at FVB/n, N5.
(A–H) Results shown represent mean ± SEM (n = 5–8 mice) and asterisks (*) indicate
statistically significant differences (p < 0.05, Mann-Whitney). Values represent average of
five high-power fields of view per mouse. Representative images of HPV16/FcRγ+/− and
HPV16/FcRγ−/− skin tissue sections at 4 months of age are shown. Red line, epidermal-
dermal interface; e, epidermis; d, dermis. Scale bars represent 50 μm. See also Figure S3.
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Figure 5. Activating FcγRs Regulate Protumor Functions of Mast Cells
(A) FcγR-dependent chemotaxis of HUVECs in response to FcγR-stimulated mast cells
isolated from FcRγ+/− or FcRγ−/− mice. BMMCs were stimulated with 2.4G2 and anti-rat
IgG (25 μg/ml; FcγR-stim.), IgGHPV16, or IgGwt (30 μg/ml). HUVEC migration in response
to conditioned medium was assessed using a Boyden chamber assay. A specific VEGF-R2
inhibitor (DC101; 100 μg/ml) was used. HUVEC migration was quantitated by enumerating
the number of migrating cells in four random fields per membrane (125× magnification).
Samples were assayed in quadruplet for each assessed condition.
(B) BMMCs from FcRγ+/− or FcRγ−/− mice were FcγR stimulated or activated with
IgGHPV16 or IgGwt in the presence or absence of the mast cell stabilizer cromolyn (10 μM).
Levels of VEGF-A in conditioned medium were assessed by ELISA. Representative
analysis from three independent experiments is shown.
(C) PBL migration in response to conditioned medium from FcRγ+/− versus FcRγ−/−
BMMCs after FcγR stimulation was evaluated with a Boyden chamber assay. PBLs
migrating to the lower chamber were visualized by H&E staining in five to eight random
fields per well. Samples were assayed in triplicate for each tested condition.
(D) FcRγ-proficient mast cells enhance tumorigenicity. PDSC5 tumor cells (blue) alone or
admixed with FcRγ+/− (red) or FcRγ−/− (green) BMMCs were injected s.c. into FVB/n
(WT) or kitsh/sh (gray) mice at a 1:1 ratio. The asterisk (*) indicates statistically significant
differences between PDSC5 cells in combination with FcRγ+/− versus FcRγ−/− BMMCs.
The number sign (#) indicates statistically significant differences between tumor growth in
syngeneic FVB/n or kitsh/sh mice.
(E) FcRγ-proficient mast cells induce angiogenesis and leukocyte infiltration of
transplantable tumors. Blood vessels and leukocyte infiltration were evaluated by CD31 and
Gr1 IHC. Values represent average of five high-power fields of view per tumor and six to
ten tumors per category.
(A–E) Data are represented as means ± SEM; *p < 0.05; **p < 0.01 (unpaired t test).
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Figure 6. Tumor-Promoting Activities of CD11b+Gr1+/− Myeloid Cells in HPV16 Mice
(A) Representative micrographs depicting morphology of CD11b+Gr1+ and CD11b+Gr1−
myeloid cells purified by FACS sorting from skin or spleen of HPV16 mice (4 month) and
visualized via May-Grünwald-Giemsa staining (scale bars represent 50 μm).
(B) Macrophages and spleen IMCs enhance tumorgenicity. Tumor growth of PDSC5 cells
alone (red line) or admixed with either IMCs (blue line) or macrophages (MØ, green line;
PDSC5/leukocyte = 10:1) FACS sorted from neoplastic skin (top graph) or spleen (bottom
graph) of HPV16 mice at 4 months of age. Asterisks (*) and number signs (#) indicate
statistically significant differences between PDSC5 cells alone and PDSC5 in combination
with macrophages and IMCs, respectively.
(C) Macrophages and spleen IMCs enhance tumor angiogenesis. Blood vessels in PDSC5
subcutaneous tumors were evaluated by CD31 and Gr1 IHC. Values represent average of
five high-power fields of view per tumor and six to ten tumors per category.
(D) FcγR-stimulated macrophages are chemotactic toward endothelial cells. Macrophages
and IMCs were purified by FACS sorting from neoplastic skin and spleens of 4-month-old
HPV16 mice and treated for IgG-dependent FcγR stimulation and HUVEC chemotaxis was
evaluated in a Boyden chamber assay.
(B–D) Data are represented as means ± SEM (*, #p < 0.01; **p < 0.001, unpaired t test). See
also Figure S4 and Table S1.
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Figure 7. FcRγ Expression Regulates Proangiogenic and Protumorigenic Properties of
Macrophages
(A and B) FcRγ expression regulated macrophage protumor activity. PDSC5 tumor cells
were injected alone (blue) or admixed with macrophages derived from neoplastic skin
(MØskin) of either HPV16/FcRγ+/− (red) or HPV16/FcRγ−/− (green) mice (A) or instead
from bone marrow-derived macrophages (MØBM) isolated from FcRγ+/− (red) or FcRγ−/−
(green) mice (B). The asterisk (*) indicates statistically significant differences between
PDSC5 cells admixed with FcRγ+/− versus FcRγ−/− macrophages. The number sign (#)
indicates statistically significant differences between PDSC5 alone and PDSC5 admixed
with FcRγ−/− macrophages. Data are represented as means ± SEM; p < 0.05, unpaired t test.
(C) Genes differentially expressed in macrophages isolated from neoplastic skin of HPV16/
FcRγ−/− versus HPV16/FcRγ+/− mice. mRNA expression levels in macrophages from
HPV16/FcRγ−/− neoplastic skin (4 month old) are indicated as fold change as compared to
HPV16/FcRγ+/− macrophages with ΔCT of each gene calculated with β2-microglobulin as
endogenous control. Expression was considered as statistically significantly deregulated
when p < 0.05 (t test, FcRγ−/− versus FcRγ+/−).
(D) Quantitative real-time PCR analysis of Cxcl10 and Cxcr3 mRNA expression in ear
tissue from 4-month-old negative littermate (−LM), HPV16, HPV16/JH−/−, and HPV16/
FcRγ−/− mice (n = 3–5 mice/cohort). *p < 0.05; **p < 0.01, unpaired t test.
(E) VEGF165-induced (100 ng/ml) HUVEC chemotaxis was evaluated in a Boyden chamber
assay after pretreatment with recombinant CXCL10 (100 ng/ml) in the presence or absence
of CXCR3 blocking antibody (10 μg/ml). *p < 0.05; **p < 0.01, unpaired t test.
(F) Macrophages isolated from HPV16/FcRγ−/− mice exhibit angiostatic activity. HUVEC
chemotaxis in a Boyden chamber assay was evaluated after pretreatment with conditioned
medium isolated from macrophages (purified from skin of HPV16/FcRγ+/− or HPV16/
FcRγ−/− mice) following activation with LPS (10 ng/ml) and αCXCR3 blocking Ig (10 μg/
ml). *, p < 0.05; **, p < 0.01, unpaired t test.
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(E and F) Pretreated HUVECs were evaluated for chemotactic migration in response to
VEGF (100 ng/ml) using a Boyden chamber assay. Quantitative values reflect the number of
migrating HUVECs averaged from four to five high-power fields per insert and four inserts
per treatment ± SEM. At least three independent analyses were performed and one
representative experiment is shown. See also Figure S5 and Table S1.
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Figure 8. Activation of the FcRγ Pathway in Mast Cells and Macrophages by Humoral
Immunity Regulates Squamous Carcinogenesis of HPV16 Mice
HPV16 oncogene expression initiates keratinocytes and triggers early neoplastic progression
accompanied by neo- and self-antigen presentation, peripheral B cell activation/maturation,
and secretion of Igs. Autoantibodies subsequently accumulate in dermal stroma of neoplastic
tissue as vasculature becomes initially angiogenic and “leaky.” IgGs interact with Fcγ
receptors on resident and recruited myeloid cells where they induce differential recruitment
of leukocytes from peripheral blood and regulate mast cell and macrophage bioeffector
functions once present in neoplastic tissue. FcRγ deficiency not only impairs the
protumorigenic properties of mast cells and macrophages but also reprogram macrophages
leading to enhanced angiostatic and M1 bioactivity.
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